By Jennifer FuchsPublished Nov 07, 2017 12:38:33Hepatitis A vaccine candidates have been approved in the U.S. and around the world, but it is the hepatitis A C virus that is causing the most serious infections in the United States.
A new vaccine candidate developed by Pfizer, which has been approved to treat the virus, is expected to be available by the end of 2019, according to the company.
The vaccine, called M-CAR-P, has been tested in two large clinical trials, which are the first in a larger effort to determine the efficacy of the vaccine in humans.
It is expected that the vaccine will be able to help protect against the first phase of the pandemic, which began in October and is expected start affecting most of the world by December.
The second phase of pandemic will begin in December.
“Our research team has identified a number of promising candidates for the Phase 3 phase 3 of M-CAR-P,” said Dr. James F. Wunderlich, chief executive of Pfizer.
“Our focus is on determining the most effective and safest combination of the vaccines that we can create to protect against hepatitis A. That will help ensure that we don’t see any adverse reactions to this vaccine, which is important for patients with active hepatitis A.”
The U.K.-based company also said it has begun recruiting a panel of experts to provide advice to the new vaccine, including clinical trials experts from Pfizer and others.
The vaccine is an antibody that will bind to and block the virus’ RNA, a genetic code that can be manipulated to make it more effective at protecting against the disease.
The virus can then infect cells or proteins in the body, creating a biofilm.
In a study published last month in the journal Science Translational Medicine, researchers led by Dr. Wundrich showed that in patients with chronic hepatitis A, the new drug had fewer side effects than a placebo, including fewer cases of infection and fewer cases requiring hospitalization.
The new drug has been shown to significantly reduce the incidence of acute liver failure in the trials.
But researchers said it is not yet clear how well it will work in people with active viral hepatitis A who have been given other vaccines.
The study was conducted at the University of Michigan and the University at Buffalo.
In addition to Dr. Fuchs, other authors of the Science Trans Lational Medicine study included Dr. Eric Kochel of the University College London and Dr. John Pfeifer of the Department of Molecular and Cell Biology, and Drs.
Paul M. Krosnick, the University Hospital of Basel and Professor Jean-François A. Bouchard of the Institut Pasteur.
The research was supported by the U-M Hepatitis Research Program, the National Institutes of Health, the Bill and Melinda Gates Foundation, and the Umeå Research Fund.